A Hemorrhage of Off-Label Use

The authors highlight the pervasive problem of off-label drug prescribing unsupported by evidence, using recombinant factor VIIa as a case study. They argue that the gap between FDA approval requirements and the freedom physicians have to prescribe off-label creates significant safety and cost concerns.